Healthcare
Tuesday, April 26, 2016
BRIEF-Sarepta statement on advisory committee outcome for use of Eteplirsen in treatment of Duchenne muscular dystrophy
* Sarepta issues statement on advisory committee outcome for
use of Eteplirsen in treatment of duchenne muscular dystrophy
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment